Sterling Capital Management’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
Sterling Capital Management's MLYS Position: Q3 2026 in Review
Sterling Capital Management increased its Mineralys Therapeutics (MLYS) stake by 902% in Q3 2026, buying an estimated $49.6K and bringing the position to 2,024 shares worth $50.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1757.
Sterling Capital Management first reported a position in MLYS in Q3 2024 and has held it in 9 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- Sterling Capital Management held 2,024 shares of Mineralys Therapeutics worth $50.9K as of Q3 2026.
- Sterling Capital Management bought 1,822 Mineralys Therapeutics shares in Q3 2026, an estimated $49.6K.
- Mineralys Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1757 holding.
- Sterling Capital Management first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 9 quarters since.
- 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.